NCT03417284 · REGISTRY CONDITION SEARCH

Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1, PHASE2
Status at capture: COMPLETED
Registry last update: 2025-05-01

This phase I/II trial studies the side effects and best dose of melphalan hydrochloride in treating participants with newly-diagnosed multiple myeloma who are undergoing a donor stem cell transplantation. Giving chemotherapy before a donor stem cell transplantation helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the participant, they may help the participant's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving melphalan hydrochloride before a donor stem cell transplantation may work better than standard chemotherapy in helping to prevent multiple myeloma from coming back.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Optimal Dose and Schedule of Evomela Prior to Autologous Transplant.

→

outcome · POSTED

Progression-free Survival (PFS)

→

outcome · POSTED

Treatment Related Mortality (TRM).

→

outcome · POSTED

Number of Participants That Have Achieved Complete Response (CR).

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Patients with non-relapsed multiple myeloma in complete response (CR), partial remission (PR), very good partial remission (VGPR), or symptomatic stable disease (no evidence of progression) including patients with light chain multiple myeloma (MM) detected in the serum by free light chain assay OR * Patients with non-secretory multiple myeloma (absence of a monoclonal protein \[M protein\] in serum as measured by electrophoresis \[serum protein electrophoresis (SPEP)\] and immunofixation (serum immunofixation electrophoresis \[SIFE\]) and the absence of Bence Jones protein in the urine \[urine protein electrophoresis (UPEP)\] defined by use of conventional electrophoresis and immunofixation \[urine immunofixation electrophoresis (UIFE) techniques\]) but with measurable disease on imaging studies like magnetic resonance imaging (MRI), computed tomography (CT) scan or positron emission tomography (PET) scan. * Patients who have received at least two cycles of initial systemic therapy and are within 2 to 12 months of the first dose. Mobilization therapy is not considered initial therapy. * Karnofsky performance score 70% or higher. * Left ventricular ejection fraction at rest \> 40% within 3 months of registration. * Bilirubin \< 2 x the upper limit of normal (except patients with Gilbert syndrome in whom bilirubin level of \> 2 x upper normal limit will be allowed) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 x the upper limit of normal. * Creatinine clearance of \>= 40 mL/min, estimated or calculated using the Cockcroft-Gault equation. * Pulmonary function: diffusing capacity of the lungs for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), forced vital capacity (FVC) \> 50% of predicted value (corrected for hemoglobin) within 3 months of registration. * All female and male subjects of reproductive potential must consent to the use of effective contraceptive methods as advised by the study doctor during treatment. * Signed informed consent form. Exclusion Criteria: * Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication and progression of clinical symptoms). * Patients seropositive for the human immunodeficiency virus (HIV). * Patients with history of myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. * Patients participating in an investigational new drug protocol within 14 days before enrollment. * Female patients who are pregnant (positive beta-human chorionic gonadotropin \[b-HCG\]) or breast feeding. * Prior hematopoietic cell transplantation allogeneic or autologous (A prior autologous HCT will be allowed as long as it was part of tandem transplantation). * Prior organ transplant requiring immunosuppressive therapy
healthy Volunteers: false
maximum Age: 70 Years
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
PREPARATIVE REGIMEN: Participants receive melphalan hydrochloride IV over 30-60 minutes on day -2. TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes. POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10\^9/L.
intervention Names
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Biological: Filgrastim-sndz
Drug: Melphalan Hydrochloride
label
Group 1 (melphalan hydrochloride, HSCT, filgrastim)
type
EXPERIMENTAL
description
PREPARATIVE REGIMEN: Participants receive melphalan hydrochloride IV over 8-9 hours on day -2. TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes. POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10\^9/L.
intervention Names
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Biological: Filgrastim-sndz
Drug: Melphalan Hydrochloride
label
Group 2 (melphalan hydrochloride, HSCT, filgrastim)
type
EXPERIMENTAL

interventions

arm Group Labels
Group 1 (melphalan hydrochloride, HSCT, filgrastim)
Group 2 (melphalan hydrochloride, HSCT, filgrastim)
description
Undergo HSCT
name
Autologous Hematopoietic Stem Cell Transplantation
other Names
AHSCT
Autologous Hematopoietic Cell Transplantation
Autologous Stem Cell Transplantation
Stem Cell Transplantation, Autologous
type
PROCEDURE
arm Group Labels
Group 1 (melphalan hydrochloride, HSCT, filgrastim)
Group 2 (melphalan hydrochloride, HSCT, filgrastim)
description
Given SC
name
Filgrastim-sndz
other Names
Filgrastim Biosimilar Filgrastim-sndz
Zarxio
type
BIOLOGICAL
arm Group Labels
Group 1 (melphalan hydrochloride, HSCT, filgrastim)
Group 2 (melphalan hydrochloride, HSCT, filgrastim)
description
Given IV
name
Melphalan Hydrochloride
other Names
Alkeran
Alkerana
Evomela
type
DRUG

Study design

allocation

RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 62
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Dose limiting toxicity will be defined as grade 4 mucositis or any grade 4 or 5 non-hematologic or non-infectious toxicity occurring within 30 days from the start of infusion.
measure
Optimal Dose and Schedule of Evomela Prior to Autologous Transplant.
time Frame
Within 30 days after the start of infusion

secondary Outcomes

description
Number of participants that are still alive and disease free one year post autologous transplant.
measure
Progression-free Survival (PFS)
time Frame
From the date of Evomela injection up to 1 year
description
Number of participants expired from non-disease relapse within 90 days post transplant
measure
Treatment Related Mortality (TRM).
time Frame
At day 90 post-transplant
description
Number of participants that have achieved Complete response (CR). Complete response definition is negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow aspirates.
measure
Number of Participants That Have Achieved Complete Response (CR).
time Frame
At 90 days post-transplant

Full study description

brief Summary: This phase I/II trial studies the side effects and best dose of melphalan hydrochloride in treating participants with newly-diagnosed multiple myeloma who are undergoing a donor stem cell transplantation. Giving chemotherapy before a donor stem cell transplantation helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the participant, they may help the participant's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving melphalan hydrochloride before a donor stem cell transplantation may work better than standard chemotherapy in helping to prevent multiple myeloma from coming back.
detailed Description: PRIMARY OBJECTIVES: I. To determine the optimal dose and schedule of melphalan for injection (melphalan hydrochloride \[Evomela\]) prior to autologous hematopoietic stem cell transplantation (auto-HCT) for multiple myeloma (MM). II. To collect the pharmacokinetic data and compare the exposure-response evaluations between the 2 infusion schedules. SECONDARY OBJECTIVES: I. To determine the incidence of treatment related mortality (TRM) at day 90 after auto-HCT in newly diagnosed myeloma patients treated on different schedules and doses of Evomela. II. To determine the rate of minimal residual disease (MRD) negative complete response (CR) rate at day 90 after auto-HCT in newly diagnosed myeloma patients treated on different schedules and doses of Evomela. III. To determine the progression-free survival (PFS) after auto-HCT in newly diagnosed myeloma patients treated on different schedules and doses of Evomela. OUTLINE: This is a phase I, dose escalation study of melphalan hydrochloride followed by a phase II study. PREPARATIVE REGIMEN: Participants are randomized to 1 of 2 groups. GROUP 1: Participants receive melphalan hydrochloride intravenously (IV) over 30-60 minutes on day -2. GROUP 2: Participants receive melphalan hydrochloride IV over 8-9 hours on day -2. TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes. POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz subcutaneously (SC) once daily (QD) starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an absolute neutrophil count (ANC) of 0.5 x 10\^9/L. After completion of study treatment, participants are followed up at 3 months, every 3 months for 1 year, and then annually for 1 year.

Source references

references

citation
Bashir Q, Thall PF, Kawedia J, Xu X, Knape CG, Delgado R, Nieto Y, Saini NY, Aljawai YM, Srour SA, Ramdial JL, Hosing C, Popat UR, Oran B, Kebriaei P, Ahmed S, Pasvolsky O, Patel KK, Thomas SK, Gaballa MR, Ye JC, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Phase I/II Trial of Evomela for Autologous Transplant in Myeloma: Schedule Optimization and Matched Comparison with MEL200. Blood Adv. 2026 Jul 31:bloodadvances.2026020293. doi: 10.1182/bloodadvances.2026020293. Online ahead of print.
pmid
42537695
type
DERIVED